Work

A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis

Year: 2025

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: New England Journal of Medicine

DOI: 10.1056/nejmoa2501561

Authors: Richard J. Nowak, Michael Benatar, Emma Ciafaloni, James F. Howard, M. Isabel Leite, Kimiaki Utsugisawa, John Vissing, Mikhail Rojavin, Qing Li, Fengming Tang, Yanping Wu, Nishi Rampal, Sue Cheng

Institutions: Yale University, University of Miami, University of Rochester, University of North Carolina at Chapel Hill, University of Oxford, General Hanamaki Hospital, University of Copenhagen, Rigshospitalet, Amgen (United States)

Language: English

Topic: Myasthenia Gravis and Thymoma

Subfield: Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Amgen

OpenAlex ID: W4409251704

FWCI: 39.87

Cites: 27

Cited by: 73

Related to: 10